Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives

References

• SumarMLDasoukiMJSchofieldPJPhysical and linkage mapping of human carbamyl phosphate synthetase I (CPS1) and reassignment from 2p to 2q35Cytogenet Cell Genet19957132662677587391
   PubMedGoogle Scholar
• ChoiJHLeeBHKimJHClinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiencyJ Hum Genet201560950150725994866
   PubMed Web of Science ®Google Scholar
• EngelKHöhneWHäberleJMutations and polymorphisms in the human argininosuccinate synthetase (ASS1) geneHum Mutat200930330030719006241
   PubMed Web of Science ®Google Scholar
• ErezANagamaniSCLeeBArgininosuccinate lyase deficiency: argininosuccinic aciduria and beyondAm J Med Genet C Semin Med Genet20111574553
   Web of Science ®Google Scholar
• SinYYBaronGSchulzeAFunkCDArginase-1 deficiencyJ Mol Med (Berl)201593121287129626467175
   PubMed Web of Science ®Google Scholar
• BrusilowSWHorwichALUrea cycle enzymesDriverCRBeadedALSlyWSValleDThe Metabolic and Molecular Bases of Inherited DiseaseNew YorkMcGraw-Hill200119091963
   Google Scholar
• HäberleJBoddaertNBurlinaASuggested guidelines for the diagnosis and management of urea cycle disordersOrphanet J Rare Dis201273222642880
   PubMed Web of Science ®Google Scholar
• SumarMLKoelkerSFreedenbergDThe incidence of urea cycle disordersMol Genet Metab20131101–217918023972786
   PubMed Web of Science ®Google Scholar
• MsallMBatshawMLSussRBrusilowSWMellitsEDNeurologic outcome in children with inborn errors of urea synthesis: outcome of urea-cycle enzymopathiesN Engl J Med198431023150015056717540
   PubMed Web of Science ®Google Scholar
• BachmannCOutcome and survival of 88 patients with urea cycle disorders: a retrospective evaluationEur J Pediatr2003162641041612684900
   PubMed Web of Science ®Google Scholar
• NassogneMCHéronBTouatiGRabierDSaudubrayJMUrea cycle defects: management and outcomeJ Inherit Metab Dis200528340741415868473
   PubMed Web of Science ®Google Scholar
• Martín-HernándezEAldámiz-EchevarríaLCastejón-PonceEUrea cycle disorders in Spain: an observational, cross-sectional and multicentric study of 104 casesOrphanet J Rare Dis2014918725433810
   PubMed Web of Science ®Google Scholar
• KölkerSCazorlaAGValayannopoulosVThe phenotypic spectrum of organic acidurias and urea cycle disorders – part 1: the initial presentationJ Inherit Metab Dis20153861041105725875215
   PubMed Web of Science ®Google Scholar
• KölkerSValayannopoulosVBurlinaABThe phenotypic spectrum of organic acidurias and urea cycle disorders – part 2: the evolving clinical phenotypeJ Inherit Metab Dis20153861059107425875216
   PubMed Web of Science ®Google Scholar
• KrivitzkyLBabikianTLeeHSThomasNHBurk-PaullKLBatshawMLIntellectual, adaptive, and behavioral functioning in children with urea cycle disordersPediatr Res20096619610119287347
   PubMed Web of Science ®Google Scholar
• HolecekMEvidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy: therapeutic perspectivesMetab Brain Dis201429191723996300
   PubMed Web of Science ®Google Scholar
• BerryGTSteinerRDLong-term management of patients with urea cycle disordersJ Pediatr20011381 SupplS56S6111148550
   PubMed Web of Science ®Google Scholar
• BrusilowSWMaestriNEUrea cycle disorders: diagnosis, pathophysiology, and therapyAdv Pediatr1996431271708794176
   PubMedGoogle Scholar
• Urea Cycle Disorders Conference GroupConsensus statement from a conference for the management of patients with urea cycle disordersJ Pediatr20011381 SupplS1S511148543
   PubMed Web of Science ®Google Scholar
• Carbaglu [prescribing information]Lebanon (NJ)Recordati Rare Diseases2015
   Google Scholar
• PiccaSDionisi-ViciCAbeniDExtracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicatorsPediatr Nephrol2001161186286711685590
   PubMed Web of Science ®Google Scholar
• BachmannCOutcome and survival of 88 patients with urea cycle disorders: a retrospective evaluationEur J Pediatr2003162641041612684900
   PubMed Web of Science ®Google Scholar
• LewisHBStudies in the synthesis of hippuric acid in the animal organisms – II: the synthesis and rate of elimination of hippuric acid after benzoate ingestion in manJ Biol Chem1914182225231
   Google Scholar
• BatshawMLBrusilowSWaberLTreatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretionN Engl J Med198230623138713927078580
   PubMed Web of Science ®Google Scholar
• BrusilowSTinkerJBatshawMLAmino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesisScience198020744316596616243418
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationDrug approval package: Ammonul (sodium phenylacetate and sodium benzoate) injection2007 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020645s000TOC.cfmAccessed August 5, 2017
   Google Scholar
• BrusilowSWPhenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretionPediatr Res19912921471502014149
   PubMed Web of Science ®Google Scholar
• BatshawMLMacArthurRBTuchmanMAlternative pathway therapy for urea cycle disorders: twenty years laterJ Pediatr20011381 SupplS46S5511148549
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySummary of product characteristics: Pheburane Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002500/WC500147373.pdfAccessed August 5, 2017
   Google Scholar
• LeeBRheadWDiazGAPhase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia controlMol Genet Metab2010100322122820382058
   PubMed Web of Science ®Google Scholar
• DiazGAKrivitzkyLSMokhtaraniMAmmonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrateHepatology20135762171217922961727
   PubMed Web of Science ®Google Scholar
• ShneiderBLVockleyJPossible phenylacetate hepatotoxicity during 4-phenylbutyrate therapy of Byler diseaseJ Pediatr Gastroenterol Nutr201662342442826756876
   PubMed Web of Science ®Google Scholar
• IannittiTPalmieriBClinical and experimental applications of sodium phenylbutyrateDrugs R D201111322724921902286
   PubMedGoogle Scholar
• HolecekMVodenicarovovaMPhenylbutyrate exerts adverse effects on liver regeneration and amino acid concentrations in partially hepatectomized ratsInt J Exp Pathol201697327828427381898
   PubMed Web of Science ®Google Scholar
• RodneySBonehAAmino acid profiles in patients with urea cycle disorders at admission to hospital due to metabolic decompensationJIMD Rep201399710423430554
   PubMedGoogle Scholar
• HolecekMKandarRSisperaLKovarikMAcute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentrations: different sensitivity of red and white muscleAmino Acids201140257558420614225
   PubMed Web of Science ®Google Scholar
• HolecekMSpronglLTichýMEffect of hyperammonemia on leucine and protein metabolism in ratsMetabolism200049101330133411079824
   PubMed Web of Science ®Google Scholar
• BurrageLCJainMGandolfoLLeeBHSodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disordersMol Genet Metab20141131–213113525042691
   PubMed Web of Science ®Google Scholar
• Ammonaps 940 mg/g granules [summary of product characteristics]StockholmSwedish Orphan Biovitrum AB2010
   Google Scholar
• BrusilowSWMaestriNEUrea cycle disorders: diagnosis, pathophysiology, and therapyAdv Pediatr1996431271708794176
   PubMedGoogle Scholar
• GuffonNKibleurYCopaluWTissenCBreitkreutzJDeveloping a new formulation of sodium phenylbutyrateArch Dis Child201297121081108522941860
   PubMed Web of Science ®Google Scholar
• RiederMHow sweet it isn’t: a new formulation of sodium phenylbutyrate and the challenge of palatability for medicines for childrenArch Dis Child20129712108023165197
   PubMed Web of Science ®Google Scholar
• KibleurYDobbelaereDBarthMBrassierAGuffonNResults from a nationwide cohort temporary utilization authorization (ATU) survey of patients in France treated with Pheburane (sodium phenylbutyrate) taste-masked granulesPaediatr Drugs201416540741524962711
   PubMed Web of Science ®Google Scholar
• KibleurYGuffonNLong-term follow-up on a cohort temporary utilization authorization (ATU) survey of patients treated with Pheburane (sodium phenylbutyrate) taste-masked granulesPaediatr Drugs201618213914426747635
   PubMed Web of Science ®Google Scholar
• CederbaumSLeMonsCBatshawMLAlternative pathway or diversion therapy for urea cycle disorders now and in the futureMol Genet Metab2010100321922020462778
   PubMed Web of Science ®Google Scholar
• UçarSKOzbaranBAltinokYAOne year experience of Pheburane (sodium phenylbutyrate) treatment in a patient with argininosuccinate lyase deficiencyJIMD Rep201519313325665834
   PubMedGoogle Scholar
• US Department of Health and Human ServicesDietary Guidelines for Americans 2005WashingtonUS Government Printing Office2005
   Google Scholar
• OishiKDiazGGlycerol phenylbutyrate for the chronic management of urea cycle disordersExpert Rev Endocrinol Metab201495427434
   PubMedGoogle Scholar
• FerrieroRMancoGLamanteaEPhenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosisSci Transl Med20135175175ra31
   PubMed Web of Science ®Google Scholar